Drug Trial Radar · NCT06516952
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
349
Actual
Start
Oct 10, 2024
Primary completion
Oct 19, 2026
Study completion May 3, 2027
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Jul 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Conditions
- Prurigo Nodularis
Interventions
PovorcitinibDrug
Oral Tablet
PlaceboDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24Time frame: Week 24
Locations
120 sites in 12 countries. Site status is shown where the registry gives one.
Cahaba Dermatology
Birmingham, Alabama
Banner - University Medicine Multispecialty Services Clinic
Tucson, Arizona
Premier Dermatology Clinical Trials Institute At Northwest Arkansas
Fayetteville, Arkansas
Burke Pharmaceutical Research
Hot Springs, Arkansas
Dermatology Research Associates
Los Angeles, California
Northridge
Northridge, California
Rendon Center the Dermatology and Aesthetic Center
Boca Raton, Florida
Driven Research Llc
Coral Gables, Florida
University of Miami Miller School of Medicine
Miami, Florida
Research Institute of the Southeast, Llc
West Palm Beach, Florida
Illinois Dermatology Institute the Chicago Loop
Chicago, Illinois
Chicago Cosmetic Surgery and Dermatology
Chicago, Illinois
Center For Medical Dermatology and Immunology Research
Chicago, Illinois
Northshore University Healthsystem
Skokie, Illinois
Dermatology Specialists Research Indiana
Clarksville, Indiana
Oakland Hills Dermatology
Auburn Hills, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan
Somerset Skin Centre
Troy, Michigan
Medisearch Clinical Trials
Saint Joseph, Missouri
Washington University School of Medicine
St Louis, Missouri
The University of New Mexico Unm Health Sciences Center Hsc
Albuquerque, New Mexico
Montefiore Medical Center
East Syracuse, New York
Skin Center Dermatology Group
New York, New York
Stony Brook Dermatology Associates
Stony Brook, New York
Centricity Research Columbus
Columbus, Ohio
Wright State Physicians Health Center
Dayton, Ohio
International Clinical Research Tennessee Llc
Murfreesboro, Tennessee
Dermatology Treatment and Research Center
Dallas, Texas
Sweetwater Dermatology
Sugar Land, Texas
Center For Clinical Studies
Webster, Texas
Frontier Dermatology
Mill Creek, Washington
Conexa Investigacion Clinica S.A.
Buenos Aires, Argentina
Cedic - Centro de Investigacion Clinica
Buenos Aires, Argentina
Instituto de Neumonologia Y Dermatologia
Buenos Aires, Argentina
Instituto de Investigaciones En Alergia Y Enfermedades Respiratorias (Inaer)
Buenos Aires, Argentina
Centro de Investigaciones Medicas Mar Del Plata
Mar del Plata, Argentina
Instituto Especialidades de La Salud Rosario - Clinica Del Torax
Rosario, Argentina
Investigaciones Reumatologicas Tucuman S.R.L.
San Miguel de Tucumán, Argentina
Medical University Graz University Clinic For Dermatology and Venerology
Graz, Austria
Wiener Krankenanstaltenverbund (Kav) - Krankenhaus Hietzing Mit Neurologischem Zentrum Rosenhuegel
Vienna, Austria
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.